Saturday 17 October 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.41
0.53
−5.33%
Follow INKT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 57.94% | 72.34% | 73.90% | 79.54% |
+8 more TTM periods Free account |
|
| (187.78%) | (170.31%) | (125.20%) | (110.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(555.09%) | (403.61%) | (1,034.81%) | (807.54%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.36) | (1.32) | (1.39) | (1.26) | |
Free Cash Flow |
(6.83) | (6.32) | (5.93) | (5.58) | |
| Other line items | |||||
Cash ROIC |
130.82% | 199.88% | 683.10% | (726.26%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.60 | 0.51 | 0.47 | 0.45 | |
Depreciation/Fixed assets |
0.48 | 0.47 | 0.46 | 0.46 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.36) | (1.32) | (1.39) | (1.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates